Відмінності між версіями «Le illness in peripheral blood or bone marrow even when»
м |
м |
||
| Рядок 1: | Рядок 1: | ||
| − | + | A detailed explanation in the statistical strategies is out there inside the On the net Supplement.Final results Baseline characteristicsThe median age of your complete cohort was 58 years (range, 27-93 years), along with the percentage of patients older than 70 years was 22 . Based on D ner's hierarchical model, 17/221 (8 ) and 40/221 (18 ) individuals had 17p deletion and 11q deletion, respectively.Le disease in peripheral blood or bone marrow even when extremely sensitive immunophenotypic or molecular strategies are utilised to look for residual disease. These individuals are viewed as to have achieved a minimal residual disease (MRD) negative status.17-20 Various phase II trials have demonstrated that sufferers attaining MRD negativity possess a signif-icantly longer survival than those who stay MRD optimistic, and this can be true for individuals treated with standard chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Additionally, a phase III trial performed by the German CLL Study Group (GCLLSG) not too long ago revealed that sufferers getting MRD negativity had considerably longer progression-free and general survivals, irrespectively in the treatment received.18 However, having said that, some of these research have been flawed by inappropriate statistical analysis, especially the measurement of time-to-event outcomes from remedy initiation.27 Additionally, there are lots of caveats towards the use of MRD analysis in individuals with CLL.28 Very first, CLL remains incurable and no less than 30 of individuals who reach MRD negativity soon after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC at some point encounter a illness relapse inside five years.18 Secondly, unlike the situation in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there's no formal proof of a therapeutic benefit of re-treatment upon documentation of MRD positivity right after an initial MRD-negative response in comparison to treatment at the time of clinical relapse. In truth, very couple of studies have demonstrated a clear benefit from MRD eradication or consolidation therapy in CLL,31,32 and a few with the methods tested, even though effective, resulted in substantial toxicity.33-35 Thirdly, it could possibly be argued that MRD assessment is just a surrogate for evalution of other adverse prognostic markers given that, for [http://www.nanoplay.com/blog/21732/100-mg-day-the-dose-most-frequently-used/ one hundred mg/day (the dose most frequently {used] instance, patients with a 17p014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2013.099796 The on the net version of this short article has a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. Correspondence: jdelgado@clinic.ub.eshaematologica | 2014; 99(five)R. Santacruz et al.deletion possess a larger probability of remaining MRD-positive following therapy compared to patients without this chromosome abnormality.18 For all these causes, existing suggestions for the management of individuals with CLL recommend MRD assessment only within clinical trials with "curative intention".36 With all this details in mind, we retrospectively evaluated the impact of MRD on the outcome of individuals with CLL receiving any front-line therapy in the context of an incredibly detailed prognostic evaluation, like recently described recurrent gene mutations.survival and general survival have been calculated utilizing a landmark evaluation. All calculations were performed working with either SPSS, version 18.0, or R, version 3.0.1. Two-sided P values 0.05 had been considered statistically substantial. | |
Версія за 12:16, 17 січня 2018
A detailed explanation in the statistical strategies is out there inside the On the net Supplement.Final results Baseline characteristicsThe median age of your complete cohort was 58 years (range, 27-93 years), along with the percentage of patients older than 70 years was 22 . Based on D ner's hierarchical model, 17/221 (8 ) and 40/221 (18 ) individuals had 17p deletion and 11q deletion, respectively.Le disease in peripheral blood or bone marrow even when extremely sensitive immunophenotypic or molecular strategies are utilised to look for residual disease. These individuals are viewed as to have achieved a minimal residual disease (MRD) negative status.17-20 Various phase II trials have demonstrated that sufferers attaining MRD negativity possess a signif-icantly longer survival than those who stay MRD optimistic, and this can be true for individuals treated with standard chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Additionally, a phase III trial performed by the German CLL Study Group (GCLLSG) not too long ago revealed that sufferers getting MRD negativity had considerably longer progression-free and general survivals, irrespectively in the treatment received.18 However, having said that, some of these research have been flawed by inappropriate statistical analysis, especially the measurement of time-to-event outcomes from remedy initiation.27 Additionally, there are lots of caveats towards the use of MRD analysis in individuals with CLL.28 Very first, CLL remains incurable and no less than 30 of individuals who reach MRD negativity soon after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC at some point encounter a illness relapse inside five years.18 Secondly, unlike the situation in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there's no formal proof of a therapeutic benefit of re-treatment upon documentation of MRD positivity right after an initial MRD-negative response in comparison to treatment at the time of clinical relapse. In truth, very couple of studies have demonstrated a clear benefit from MRD eradication or consolidation therapy in CLL,31,32 and a few with the methods tested, even though effective, resulted in substantial toxicity.33-35 Thirdly, it could possibly be argued that MRD assessment is just a surrogate for evalution of other adverse prognostic markers given that, for one hundred mg/day (the dose most frequently {used instance, patients with a 17p014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2013.099796 The on the net version of this short article has a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. Correspondence: jdelgado@clinic.ub.eshaematologica | 2014; 99(five)R. Santacruz et al.deletion possess a larger probability of remaining MRD-positive following therapy compared to patients without this chromosome abnormality.18 For all these causes, existing suggestions for the management of individuals with CLL recommend MRD assessment only within clinical trials with "curative intention".36 With all this details in mind, we retrospectively evaluated the impact of MRD on the outcome of individuals with CLL receiving any front-line therapy in the context of an incredibly detailed prognostic evaluation, like recently described recurrent gene mutations.survival and general survival have been calculated utilizing a landmark evaluation. All calculations were performed working with either SPSS, version 18.0, or R, version 3.0.1. Two-sided P values 0.05 had been considered statistically substantial.
